Subcutaneous methotrexate for symptomatic control of severe recalcitrant psoriasis: safety, efficacy, and patient acceptability.

about

Subcutaneous methotrexate for symptomatic control of severe recalcitrant psoriasis: safety, efficacy, and patient acceptability.

Item

http://www.wikidata.org/entity/Q54956831

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Subcutaneous methotrexate for ...... cy, and patient acceptability.

@en

Subcutaneous methotrexate for ...... cy, and patient acceptability.

@nl

type

Item

label

Subcutaneous methotrexate for ...... cy, and patient acceptability.

@en

Subcutaneous methotrexate for ...... cy, and patient acceptability.

@nl

prefLabel

Subcutaneous methotrexate for ...... cy, and patient acceptability.

@en

Subcutaneous methotrexate for ...... cy, and patient acceptability.

@nl

P1476

Subcutaneous methotrexate for ...... cy, and patient acceptability.

@en

P2093

Iviensan F Manalo

http://www.w3.org/2001/XMLSchema#string

Jashin J Wu

http://www.w3.org/2001/XMLSchema#string

Kathleen E Gilbert

http://www.w3.org/2001/XMLSchema#string

P2860

LETTER TO THE EDITOR Subcutaneous (SC) Methotrexate (MTX) is Better and Well-Tolerable than Oral MTX in Rheumatoid Arthritis Patients, Switched from Oral to SC Administration Due to Gastrointestinal Side Effects

Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature.

Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity.

Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration.

Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience.

Nearly pain-free self-administration of subcutaneous methotrexate with an autoinjector: results of a phase 2 clinical trial in patients with rheumatoid arthritis who have functional limitations

Novel therapies for psoriasis.

Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis.

Preference, satisfaction and usability of subcutaneously administered methotrexate for rheumatoid arthritis or psoriatic arthritis: results of a postmarketing surveillance study with a high-concentration formulation.

Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis.

P304

65-70

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/PTT.S58010

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29387583

http://www.w3.org/2001/XMLSchema#string

P932

5683114

http://www.w3.org/2001/XMLSchema#string